Orrin Hatch actually said...

"If the FDA is updating its thinking in its regulatory capacity, I would think that finalizing guidance provides more certainty for the industry than having a lingering updated draft guidance."

"I completely agree and support FDA finalizing its guidance on good manufacturing practices for the cosmetics industry."

"I fear that, as has been intimated, the current review process that the FDA has would not be adequate to accommodate all of the tests that fall under their definition of LDTs, and that without further..."

"Legislative solutions that incorporate all stakeholders are more transparent and could be more appropriate to ensuring oversight for high-risk tests."